MADRID, April 14 (Reuters) - Spanish drug maker Grifols (GRLS.MC), opens new tab, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Barcelona-based Grifols has denied wrongdoing, describing the allegations as “false information and ...

Canadian investment fund Brookfield (NYSE:BAM) resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols (NASDAQ:GRFS), El Confidencial reported on Wednesday, citing industry ...

Private equity firm Brookfield has said it is withdrawing from negotiations to take over Grifols, sparking a slump in the Spanish pharma group's share price. The Canadian investment group said it had ...

(Bloomberg) -- Four investment groups with ties to the family that owns about 35% of Grifols SA confirmed they are in talks with Brookfield Asset Management Ltd. over a potential offer for the Spanish ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

The embattled Spanish drugmaker Grifols SA is in talks with banks to refinance bonds due next year and extend a revolving credit line — together about €1.4 billion ($1.48 billion) — as it seeks to ...

Grifols’ admissions are the latest development since activist short seller Gotham City Research first took aim at the company on Jan. 9, 2024, releasing a scathing report attacking the company’s ...

Mason Capital Management, a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols (GRFS) class A shares, sent a letter to the Grifols board, which reads in part: ...

Spanish plasma company Grifols SA is in advanced talks to sell part of its minority stake in Shanghai RAAS Blood Products Co. to China Merchants Group Ltd., people with knowledge of the matter said.

Grifols plans to release Phase III results of its long-term albumin treatment designed to increase survival time in patients with decompensated cirrhosis and ascites in 2024, says chief scientific ...

Grifols has denied media reports suggesting that the Spanish pharmaceutical company was in talks with private equity fund Brookfield for another takeover bid. In a statement Wednesday to Spain's ...